This Article Full Text Full Text (PDF) All Versions of this Article: 90/1/128    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barker, J. M. Articles by Gottlieb, P. A. Search for Related Content PubMed PubMed Citation Articles by Barker, J. M. Articles by Gottlieb, P. A. Related Collections Adrenal and Hypertension Diabetes and Insulin

Endocrine and Immunogenetic Testing in Individuals with Type 1 Diabetes and 21-Hydroxylase Autoantibodies: Addison’s Disease in a High-Risk Population

Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado 80262

Address all correspondence and requests for reprints to: Dr. Jennifer M. Barker, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B-140, Denver, Colorado 80262. E-mail: jennifer.barker{at}uchsc.edu.

Individuals with type 1 diabetes mellitus (T1D) at risk for Addison’s disease (AD) can be identified with RIAs for autoantibodies to the adrenal antigen 21-hydroxylase (21-OHAA). Screening individuals with T1D for 21OH-AA shows a relatively high prevalence of positive autoantibodies (1.4%, 38 of 2696 subjects). After detection of 21-OHAA, individuals were evaluated with endocrine testing, including baseline cortisol, ACTH, and plasma renin activity and low (1 µg) and high (250 µg) dose cortrosyn stimulation. Typing for DR and DQ alleles and for the major histocompatibility complex class I-related chain A (MICA) gene polymorphisms was performed. Six individuals were diagnosed with AD; five were identified on initial endocrine evaluation. Follow-up over 2.9 yr yielded one additional diagnosis of AD. Endocrine testing showed a correlation between baseline ACTH and peak cortisol (r = –0.61; P < 0.0001), baseline and peak cortisol (r = 0.70; P < 0.0001), and stimulated cortisol after low- and high-dose testing (r = 0.92; P < 0.0001). DR3-DQ2/DR4-DQ8 with DRB1* 0404 was associated with expression of 21-OHAA. At 2 yr, individuals homozygous for MICA5.1 had AD-free survival of 60% compared with 100% AD-free survival in those who were not homozygous for MICA5.1. Homozygosity for MICA5.1 may increase progression to overt AD among 21-OHAA-positive individuals.

This article has been cited by other articles:

				Z Gombos, R Hermann, M Kiviniemi, S Nejentsev, K Reimand, V Fadeyev, P Peterson, R Uibo, and J Ilonen Analysis of extended human leukocyte antigen haplotype association with Addison's disease in three populations Eur. J. Endocrinol., December 1, 2007; 157(6): 757 - 761. [Abstract] [Full Text] [PDF]

				J. M. Wenzlau, K. Juhl, L. Yu, O. Moua, S. A. Sarkar, P. Gottlieb, M. Rewers, G. S. Eisenbarth, J. Jensen, H. W. Davidson, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes PNAS, October 23, 2007; 104(43): 17040 - 17045. [Abstract] [Full Text] [PDF]

				T. Likhari, S. Magzoub, M. J Griffiths, H. N Buch, and R Gama Screening for Addison's disease in patients with type 1 diabetes mellitus and recurrent hypoglycaemia Postgrad. Med. J., June 1, 2007; 83(980): 420 - 421. [Abstract] [Full Text] [PDF]

				M. Ghaderi, G. Gambelunghe, C. Tortoioli, A. Brozzetti, K. Jatta, B. Gharizadeh, A. De Bellis, F. Pecori Giraldi, M. Terzolo, C. Betterle, et al. MHC2TA Single Nucleotide Polymorphism and Genetic Risk for Autoimmune Adrenal Insufficiency J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4107 - 4111. [Abstract] [Full Text] [PDF]

				J. M. Barker Type 1 Diabetes-Associated Autoimmunity: Natural History, Genetic Associations, and Screening J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1210 - 1217. [Abstract] [Full Text] [PDF]